Search

Your search keyword '"Giagulli, Vito Angelo"' showing total 203 results
Start Over Author "Giagulli, Vito Angelo"
203 results on '"Giagulli, Vito Angelo"'

5. Obesity: The Rule or Not

Author

Castellana, Marco, Chang, Simon, Procino, Filippo, De Pergola, Giovanni, Triggiani, Vincenzo, Giagulli, Vito Angelo, Jannini, Emmanuele A., Series Editor, Foresta, Carlo, Series Editor, Lenzi, Andrea, Series Editor, Maggi, Mario, Series Editor, Garolla, Andrea, editor, and Corona, Giovanni, editor

Published
2020
Full Text
View/download PDF

6. Once-Weekly Insulin Icodec in Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Clinical Trials (ONWARDS Clinical Program).

Author

Lisco, Giuseppe, De Tullio, Anna, De Geronimo, Vincenzo, Giagulli, Vito Angelo, Guastamacchia, Edoardo, Piazzolla, Giuseppina, Disoteo, Olga Eugenia, and Triggiani, Vincenzo

Subjects
TYPE 2 diabetes, INSULIN derivatives, TYPE 1 diabetes, GLYCOSYLATED hemoglobin, DRUG therapy
Abstract

Background. One hundred years have passed since the discovery of insulin, which is one of the most relevant events of the 20th century. This period resulted in extraordinary progress in the development of novel molecules to improve glucose control, simplify the insulin regimen, and ameliorate the quality of life. In late March 2024, the first once-weekly basal analog Icodec was approved for diabetes mellitus, generating high expectations. Our aim was to systematically review and meta-analyze the efficacy and safety of Icodec compared to once-daily insulin analogs in type 1 (T1D) and type 2 diabetes (T2D). Methods. PubMed/MEDLINE, Cochrane Library, and ClinicalTrials.gov were searched for randomized clinical trials (RCTs). Studies were included for the synthesis according to the following prespecified inclusion criteria: uncontrolled T1D or T2D, age ≥ 18 years, insulin Icodec vs. active comparators (Degludec U100, Glargine U100, Glargine U300, and Detemir), phase 3, multicenter, double-blind or open-label RCTs, and a study duration ≥ 24 weeks. Results. The systematic review included 4347 patients with T1D and T2D inadequately controlled (2172 randomized to Icodec vs. 2175 randomized to once-daily basal analogs). Icodec, compared to once-daily basal analogs, slightly reduced the levels of glycated hemoglobin (HbA1c) with an estimated treatment difference (ETD) of −0.14% [95%CI −0.25; −0.03], p = 0.01, and I2 68%. Patients randomized to Icodec compared to those on once-daily basal analogs had a greater probability to achieve HbA1c < 7% without clinically relevant or severe hypoglycemic events in 12 weeks from randomization with an estimated risk ratio (ERR) of 1.17, [95%CI 1.01, 1.36], p = 0.03, and I2 66%. We did not find a difference in fasting glucose levels, time in range, and time above range between Icodec and comparators. Icodec, compared to once-daily basal analogs, resulted in a slight but statistically significant weight gain of 0.62 kg [95%CI 0.25; 0.99], p = 0.001, and I2 25%. The frequency of hypoglycemic events (ERR 1.16 [95%CI 0.95; 1.41]), adverse events (ERR 1.04 [95%CI 1.00; 1.08]), injection-site reactions (ERR 1.08 [95%CI 0.62; 1.90]), and the discontinuation of treatments were similar between the two groups. Icodec was found to work better when used in a basal-only than basal-bolus regimen with an ETD in HbA1c of −0.22%, a probability of achieving glucose control of +33%, a probability of achieving glucose control without clinically relevant or severe hypoglycemia of +28%, more time spent in target (+4.55%) and less time spent in hyperglycemia (−5.14%). The risk of clinically relevant or severe hypoglycemic events was significantly higher when background glinides and sulfonylureas were added to basal analogs (ERR 1.42 [95%CI 1.05; 1.93]). Conclusion. Insulin Icodec is substantially non-inferior to once-daily insulin analogs in T2D, either insulin-naïve or insulin-treated. However, Icodec works slightly better than competitors when used in a basal-only rather than basal-bolus regimen. Weight gain and hypoglycemic risk are substantially low but not negligible. Patients' education, adequate lifestyle and pharmacological interventions, and appropriate therapy adjustments are essential to minimize risks. This systematic review is registered as PROSPERO CRD42024568680. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Is Tirzepatide the New Game Changer in Type 2 Diabetes?

Author

Lisco, Giuseppe, primary, Disoteo, Olga Eugenia, additional, De Geronimo, Vincenzo, additional, De Tullio, Anna, additional, Giagulli, Vito Angelo, additional, Guastamacchia, Edoardo, additional, De Pergola, Giovanni, additional, Jirillo, Emilio, additional, and Triggiani, Vincenzo, additional

Published
2024
Full Text
View/download PDF

8. Predicting Factors of Worse Prognosis in COVID-19: Results from a Cross-sectional Study on 52 Inpatients Admitted to the Internal Medicine Department

Author

Lisco, Giuseppe, primary, Solimando, Antonio Giovanni, additional, Stragapede, Assunta, additional, De Tullio, Anna, additional, Laraspata, Cristiana, additional, Laudadio, Carola, additional, Giagulli, Vito Angelo, additional, Prete, Marcella, additional, Jirillo, Emilio, additional, Saracino, Annalisa, additional, Racanelli, Vito, additional, and Triggiani, Vincenzo, additional

Published
2024
Full Text
View/download PDF

10. Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age

Author

Lisco, Giuseppe, primary, Disoteo, Olga Eugenia, additional, De Tullio, Anna, additional, De Geronimo, Vincenzo, additional, Giagulli, Vito Angelo, additional, Monzani, Fabio, additional, Jirillo, Emilio, additional, Cozzi, Renato, additional, Guastamacchia, Edoardo, additional, De Pergola, Giovanni, additional, and Triggiani, Vincenzo, additional

Published
2023
Full Text
View/download PDF

12. Long‐acting glucagon‐like peptide 1 receptor agonists boost erectile function in men with type 2 diabetes mellitus complaining of erectile dysfunction: A retrospective cohort study.

Author

Lisco, Giuseppe, Bartolomeo, Nicola, De Tullio, Anna, De Pergola, Giovanni, Guastamacchia, Edoardo, Jirillo, Emilio, Piazzolla, Giuseppina, Triggiani, Vincenzo, and Giagulli, Vito Angelo

Abstract

Introduction: The pharmacological management of erectile dysfunction (ED) in type 2 diabetes (T2D) is challenging as ED has a multifactorial etiology. The therapeutic potential of certain antihyperglycemic medications, such as glucagon‐like peptide 1 receptor agonists (GLP‐1RAs), has yet to be entirely studied in this setting. Material and methods: A retrospective cohort study was conducted on 108 outpatients (median age 60 [56, 65] years) with T2D complaining of ED. Data were extracted from a database referring to patients with a 1‐year follow‐up on stable treatment with metformin alone (n = 45) and GLP‐1RAs as an add‐on to metformin (n = 63). Erectile function was assessed by the 5‐item International Index of Erectile Function (IIEF5) at baseline and after 1 year of stable treatment. Values were compared between baseline (T0) and after 12 months of treatment (T12). Results: ED was confirmed in all at baseline, with an IIEF5 score range between 13 and 19 points. After 12 months of treatment, glucose management was better in patients treated with GLP‐1RAs plus metformin (HbA1c T0: 8.3 ± 0.2 vs. HbA1c T12: 7% ± 0.3%, p < 0.0001) than in those on metformin alone (HbA1c T0: 7 ± 0.5 vs. HbA1c T12: 7.3 ± 0.4, p = 0.0007). GLP‐1RAs plus metformin over metformin alone resulted in a significant weight loss (−5.82 ± 0.69 kg, p < 0.0001), reduction in waist circumference (−4.99 ± 0.6 cm, p < 0.0001), improvement in HbA1c (−0.56% ± 0.13%, p < 0.0001), and fasting plasma glucose (−25.54 ± 3.09 mg/dL, p < 0.0001), increase in total (+41.41 ± 6.11 ng/dL, p < 0.0001) and free (0.44 ± 0.09 ng/dL, p < 0.0001) testosterone levels, and gain in self‐reported erectile function (IIEF5 score: +2.26 ± 0.26, p < 0.0001). The gain in the IIEF5 score was more relevant in patients with higher baseline IIEF5 score (estimated coefficient: 0.16 ± 0.08, p = 0.045), those having carotid stenosis (0.50 ± 0.24, p = 0.045), and showing weight loss from baseline (−0.08 ± 0.03, p = 0.013). The leading determinant of the final IIEF5 score was a 1‐year treatment with GLP‐1RAs plus metformin over metformin alone (2.74 ± 0.53, p < 0.0001). Discussion: GLP‐1RAs plus metformin over metformin alone improved ED regardless of different background characteristics of patients and partially irrespective of therapeutic targets achieved after 12 months of treatment. GLP‐1RAs may have induced positive vasculature effects, resulting in improved erectile function in T2D. Conclusion: Due to the retrospective nature of the study, a potential cause–effect relationship between the use of GLP‐1RAs plus metformin over metformin alone in improving ED cannot be verified and confirmed. Randomized clinical trials are needed to provide evidence supporting the use of GLP‐1RAs for treating ED in T2D. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Obesity: The Rule or Not

Author

Castellana, Marco, primary, Chang, Simon, additional, Procino, Filippo, additional, De Pergola, Giovanni, additional, Triggiani, Vincenzo, additional, and Giagulli, Vito Angelo, additional

Published
2020
Full Text
View/download PDF

17. Hypothyroidism in older adults: A narrative review

Author

Carbotta, Giovanni, primary, Lisco, Giuseppe, primary, Fiore, Vincenzo, additional, Barucca, Alessandra, additional, Barraco, S, additional, Triggiani, Domenico, additional, Giagulli, Vito Angelo, additional, Piazzolla, Giuseppina, additional, and Triggiani, Vincenzo, additional

Published
2023
Full Text
View/download PDF

18. Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age.

Author

Lisco, Giuseppe, Disoteo, Olga Eugenia, De Tullio, Anna, De Geronimo, Vincenzo, Giagulli, Vito Angelo, Monzani, Fabio, Jirillo, Emilio, Cozzi, Renato, Guastamacchia, Edoardo, De Pergola, Giovanni, and Triggiani, Vincenzo

Abstract

Sarcopenia is an age-related clinical complaint characterized by the progressive deterioration of skeletal muscle mass and strength over time. Type 2 diabetes (T2D) is associated with faster and more relevant skeletal muscle impairment. Both conditions influence each other, leading to negative consequences on glycemic control, cardiovascular risk, general health status, risk of falls, frailty, overall quality of life, and mortality. PubMed/Medline, Scopus, Web of Science, and Google Scholar were searched for research articles, scientific reports, observational studies, clinical trials, narrative and systematic reviews, and meta-analyses to review the evidence on the pathophysiology of di-abetes-induced sarcopenia, its relevance in terms of glucose control and diabetes-related outcomes, and diagnostic and therapeutic challenges. The review comprehensively addresses key elements for the clinical definition and diagnostic criteria of sarcopenia, the pathophysiological correlation be-tween T2D, sarcopenia, and related outcomes, a critical review of the role of antihyperglycemic treatment on skeletal muscle health, and perspectives on the role of specific treatment targeting myokine signaling pathways involved in glucose control and the regulation of skeletal muscle metabolism and trophism. Prompt diagnosis and adequate management, including lifestyle inter-vention, health diet programs, micronutrient supplementation, physical exercise, and pharmaco-logical treatment, are needed to prevent or delay skeletal muscle deterioration in T2D. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Chronic Stress as a Risk Factor for Type 2 Diabetes: Endocrine, Metabolic, and Immune Implications

Author

Lisco, Giuseppe, Giagulli, Vito Angelo, De Pergola, Giovanni, Guastamacchia, Edoardo, Jirillo, Emilio, Vitale, Elsa, and Triggiani, Vincenzo

Abstract

Background: Chronic stress is a condition of pressure on the brain and whole body, which in the long term may lead to a frank disease status, even including type 2 diabetes (T2D). Stress activates the hypothalamus-pituitary-adrenal axis with release of glucocorticoids (GCs) and catecholamines, as well as activation of the inflammatory pathway of the immune system, which alters glucose and lipid metabolism, ultimately leading to beta-cell destruction, insulin resistance and T2D onset. Alteration of the glucose and lipid metabolism accounts for insulin resistance and T2D outcome. Furthermore, stress-related subversion of the intestinal microbiota leads to an imbalance of the gut-brain-immune axis, as evidenced by the stress-related depression often associated with T2D.A condition of generalized inflammation and subversion of the intestinal microbiota represents another facet of stress-induced disease. In fact, chronic stress acts on the gut-brain axis with multiorgan consequences, as evidenced by the association between depression and T2D.Oxidative stress with the production of reactive oxygen species and cytokine-mediated inflammation represents the main hallmarks of chronic stress. ROS production and pro-inflammatory cytokines represent the main hallmarks of stress-related disorders, and therefore, the use of natural antioxidant and anti-inflammatory substances (nutraceuticals) may offer an alternative therapeutic approach to combat stress-related T2D. Single or combined administration of nutraceuticals would be very beneficial in targeting the neuro-endocrine-immune axis, thus, regulating major pathways involved in T2D onset. However, more clinical trials are needed to establish the effectiveness of nutraceutical treatment, dosage, time of administration and the most favorable combinations of compounds. Therefore, in view of their antioxidant and anti-inflammatory properties, the use of natural products or nutraceuticals for the treatment of stress-related diseases, even including T2D, will be discussed. Several evidences suggest that chronic stress represents one of the main factors responsible for the outcome of T2D.

Published
2024
Full Text
View/download PDF

24. Iodine Deficiency and Iodine Prophylaxis: An Overview and Update

Author

Lisco, Giuseppe, primary, De Tullio, Anna, additional, Triggiani, Domenico, additional, Zupo, Roberta, additional, Giagulli, Vito Angelo, additional, De Pergola, Giovanni, additional, Piazzolla, Giuseppina, additional, Guastamacchia, Edoardo, additional, Sabbà, Carlo, additional, and Triggiani, Vincenzo, additional

Published
2023
Full Text
View/download PDF

26. Eating Disorders and Type 1 Diabetes: A Perspective

Author

De Pergola, Giovanni, primary, Marucci, Simonetta, additional, De Iaco, Giulia, additional, Lisco, Giuseppe, additional, Mariano, Francesco, additional, Giagulli, Vito Angelo, additional, Guastamacchia, Edoardo, additional, and Triggiani, Vincenzo, additional

Published
2022
Full Text
View/download PDF

28. Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis

Author

Lisco, Giuseppe, primary, De Tullio, Anna, additional, Disoteo, Olga, additional, De Geronimo, Vincenzo, additional, Piazzolla, Giuseppina, additional, De Pergola, Giovanni, additional, Giagulli, Vito Angelo, additional, Jirillo, Emilio, additional, Guastamacchia, Edoardo, additional, Sabbà, Carlo, additional, and Triggiani, Vincenzo, additional

Published
2022
Full Text
View/download PDF

31. Endocrine Disruptors and Obesity: An Overview

Author

De Pergola, Giovanni, primary, Murro, Isanna, additional, Lisco, Giuseppe, additional, Di Noia, Carmen, additional, Lampignano, Luisa, additional, Zupo, Roberta, additional, Giagulli, Vito Angelo, additional, Guastamacchia, Edoardo, additional, and Triggiani, Vincenzo, additional

Published
2022
Full Text
View/download PDF

32. Bone Disruption and Environmental Pollutants

Author

Giannattasio, Raffaele, primary, Triggiani, Vincenzo, primary, Lisco, Giuseppe, additional, Giagulli, Vito Angelo, additional, Settembrini, Silvio, additional, De Pergola, Giovanni, additional, Guastamacchia, Edoardo, additional, and Lombardi, Gaetano, additional

Published
2022
Full Text
View/download PDF

43. Impact of Clomiphene Citrate on the Steroid Profile in Dysmetabolic Men with Low Testosterone Levels

Author

Pelusi, Carla, additional, Fanelli, Flamina, additional, Baccini, Margherita, additional, De Pergola, Giovanni, additional, Triggiani, Vincenzo, additional, Mezzullo, Marco, additional, Fazzini, Alessia, additional, Di Dalmazi, Guido, additional, Petrovic, Biljana, additional, Paterini, Paola, additional, Labate, Antonio Maria Morselli, additional, Pagotto, Uberto, additional, and Giagulli, Vito Angelo, additional

Published
2021
Full Text
View/download PDF

45. COVID-19 and the Endocrine System: A Comprehensive Review on the Theme

Author

Lisco, Giuseppe, primary, De Tullio, Anna, additional, Stragapede, Assunta, additional, Solimando, Antonio Giovanni, additional, Albanese, Federica, additional, Capobianco, Martina, additional, Giagulli, Vito Angelo, additional, Guastamacchia, Edoardo, additional, De Pergola, Giovanni, additional, Vacca, Angelo, additional, Racanelli, Vito, additional, and Triggiani, Vincenzo, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results